EUVIMEDEUVIMED entdecken
Crossref

Tofacitinib laden MCM-48 mesoporous silica nanogel for topical psoriasis: ex vivo and in vivo therapeutic validation

Vidhi Pandya, Nidhi Trivedi, Bhupendra Prajapati, Amit Patel, Samir Patel, Alkesh Patel, Nehangi Patel, Ravish J Patel

European Journal of Pharmaceutics and Biopharmaceutics · 2026-11 · 115294

DOI: 10.1016/j.ejpb.2026.115294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026-11. Verfasst von Vidhi Pandya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus, Changa - 388421, Anand, Gujarat, India. Die Arbeit nennt 81 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a chronic immune-mediated inflammatory skin disorder wherein conventional therapies are frequently constrained by poor percutaneous absorption, high recurrence rates, and systemic or steroid-induced adverse effects. This study developed Tofacitinib-loaded MCM-48 mesoporous silica nanoparticles (TFC-MCM-48) incorporated into a Carbopol hydrogel as a topical nanocarrier system for controlled TFC delivery. Blank MCM-48 MSNs were optimized using a Box-Behnken design, followed by TFC loading through modified solvent evaporation and hydrogel formulation. A validated RP-HPLC method was used for TFC quantification. The optimized blank MCM-48 exhibited particle size of 251.8 ± 12.3 nm (PDI 0.172 ± 0.02), shifting to 311.6 ± 17.2 nm (PDI 0.326 ± 0.03) upon drug loading. Nitrogen adsorption porosimetry and low-angle XRD supported TFC incorporation with retention of the ordered mesoporous architecture and reduced drug crystallinity. The formulated TFC-MCM-48 gel was homogeneous, with a viscosity of 27,800 ± 225 cP and spreadability of 16.91 ± 0.24 g·cm/s, providing sustained in vitro release of ∼54% and greater ex vivo permeation across excised skin of ∼50% over 12 h, which maintained the physicochemical and release performance across three months of storage. In a cyclophosphamide-imiquimod-induced psoriasiform BALB/c mouse model, TFC-MCM-48 gel significantly outperformed pure drug gel, achieving a ∼92% reduction in PASI score than disease control, reducing epidermal thickness and Baker's histopathological score. This recovery was accompanied by marked attenuation of serum C-reactive protein, splenomegaly, and liver weight indices, with improved skin and spleen histology. These findings highlight TFC-MCM-48 hydrogel as a promising topical nanoplatform for Psoriasis management.

Schlagwörter

Stichwörter der Autor:innen

Box-Behnken designIn vivo studyMCM-48Mesoporous silica nanoparticlesPsoriasisTofacitinibTopical gel

Autor:innen und Institutionen

  • Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus, Changa - 388421, Anand, Gujarat, India.
  • Department of Pharmaceutics, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, Waghodia, Vadodara, Gujarat, India.
  • Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus, Changa - 388421, Anand, Gujarat, India. Electronic address: ravishpatel.ph@charusat.ac.in.

Zitieren

APA

Pandya, V., Trivedi, N., Prajapati, B., Patel, A., Patel, S., Patel, A., Patel, N., & Patel, R. J. (2026). Tofacitinib laden MCM-48 mesoporous silica nanogel for topical psoriasis: ex vivo and in vivo therapeutic validation. European Journal of Pharmaceutics and Biopharmaceutics, 115294. https://doi.org/10.1016/j.ejpb.2026.115294

Vancouver

Pandya V, Trivedi N, Prajapati B, Patel A, Patel S, Patel A, et al. Tofacitinib laden MCM-48 mesoporous silica nanogel for topical psoriasis: ex vivo and in vivo therapeutic validation. European Journal of Pharmaceutics and Biopharmaceutics. 2026:115294. doi:10.1016/j.ejpb.2026.115294

BibTeX
@article{Pandya2026,
  author = {Pandya, Vidhi and Trivedi, Nidhi and Prajapati, Bhupendra and Patel, Amit and Patel, Samir and Patel, Alkesh and Patel, Nehangi and Patel, Ravish J},
  title = {Tofacitinib laden MCM-48 mesoporous silica nanogel for topical psoriasis: ex vivo and in vivo therapeutic validation},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2026},
  pages = {115294},
  doi = {10.1016/j.ejpb.2026.115294}
}
Kostenlos starten →